Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2015, Vol. 42 Issue (1): 32-35    DOI: 10.12891/ceog1703.2015
Original Research Previous articles | Next articles
The effect of maternal polycystic ovary morphology on first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency thickness
S. Hacivelioglu1, *(), A. Uysal1, A.N. Cakir Gungor1, M. Gencer1, D.U. Cakir2, E. Cosar1
1Department of Obstetrics and Gynecology, School of Medicine, Canakkale Onsekiz Mart University, Canakkale
2Department of Clinical Biochemistry, School of Medicine, Canakkale Onsekiz Mart University, Canakkale (Turkey)
Download:  PDF(71KB)  ( 9 )
Export:  BibTeX | EndNote (RIS)      
Abstract  Objective: To evaluate the effect of maternal polycystic ovary (PCO) morphology on maternal serum free beta-human chorionic gonadotropin (β-hCG), pregnancy associated plasma protein A (PAPP-A), and nuchal translucency (NT) thickness in the first-trimester. Material and Methods: A total of 92 pregnant women in the first-trimester were included in the study. Of them, 57 had PCO morphology, and 35 women constituted the control group, with apparently normal ovaries. Maternal serum free β-hCG, PAPP-A, and NT thickness were measured and compared in all patients. Results: The multiples of median (MoM) levels of serum free β-hCG were significantly higher in the PCO morphology group compared to the normal ovary group (p = 0.024). However, the MoM levels of PAPP-A were similar in both groups (p = 0.947). No difference was found between the groups in terms of fasting glucose levels and NT measurements (p = 0.976 and 0.565, respectively). Conclusion: In pregnancies with maternal PCO morphology, the presence of higher maternal serum free β-hCG levels may require correction in the calculation of risks related to first-trimester screening for chromosomal abnormalities. Larger studies are needed to confirm our preliminary data.
Key words:  Maternal serum screening test      Nuchal translucency measurement      Polycystic ovary syndrome      Pregnancy-associated plasma protein-A     
Published:  10 February 2015     
*Corresponding Author(s):  S. Hacivelioglu     E-mail:  servetozden@comu.edu.tr

Cite this article: 

S. Hacivelioglu, A. Uysal, A.N. Cakir Gungor, M. Gencer, D.U. Cakir, E. Cosar. The effect of maternal polycystic ovary morphology on first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency thickness. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(1): 32-35.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog1703.2015     OR     https://ceog.imrpress.com/EN/Y2015/V42/I1/32

[1] Chang Liu, Minchen Dai, Lei Zhao, Fangfang Wang. The effects of Chinese herbal medicine on the pregnancy outcomes of infertile women with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer: a systematic review and meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1032-1043.
[2] Zhenzhen Lu, Ying Gao. Searching for biomarkers in the progression from polycystic ovary syndrome to endometrial carcinoma[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1117-1125.
[3] Gonca Özten Dere, Esra Uyanik, Fatih Aktoz, Pınar Çalış, Sezcan Mümüşoğlu, Hakan Yarali, Gürkan Bozdağ. The effect of laparoscopic ovarian drilling on timing of menopause in patients with polycystic ovary syndrome: 29 years of follow-up data[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 590-593.
[4] Hye Won Lee, Lin Ang, Myeong Soo Lee, Kyoung Sun Park, Jin-Moo Lee, Chang-Hoon Lee, Dong Chul Kim, Jeong-Eun Yoo, Seung-Jeong Yang, Tae-Young Choi. Prescription patterns of herbal medicine for polycystic ovarian syndrome in major Korean medicine hospitals: a multicenter retrospective study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 649-653.
[5] J. Dun, X. Wang, J. Yang, J. Xu. Clinical practice guidelines on polycystic ovary syndrome: a systematic review and comparative meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 465-471.
[6] Xiao-Tao Huang, Shao-Rong Liang, Lu Wang. Acupuncture combined with Chinese and western medicine in the treatment of polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 396-400.
[7] A. M. Maysara, A. T. Nassar, H. K. Jubran. The effect of correction of serum level of vitamin D on hyperandrogenism in women with polycystic ovary syndrome and hypovitaminosis D[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 272-276.
[8] H.M.G. Youssef, E.S. Marei, L.A. Rashed. Long non-coding RNA steroid receptor activator in polycystic ovary syndrome: possible association with metabolic syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 757-762.
[9] M.H. Vieira de Melo, M.T. Albuquerque Barbosa Cabral Micussi, R. Dias de Medeiros, R. Ney Cobucci, T.M. de Oliveira Maranhão, A.K. Gonçalves. Pelvic floor muscle thickness in women with polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 813-816.
[10] Hui-lan Wang, Xia Xu, Zhi-qun Zheng. The expression of Nuclear Factor-κB in a rat model of polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 276-279.
[11] P. Marques, F. Ferreira, A. P. Soares, J. Nunes, S. Sousa, A. Aguiar, C. Calhaz-Jorge. Clinico-biochemical characteristics of 229 Portuguese infertile women with polycystic ovary syndrome: clinical relevance and relationship with fertility treatment results[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(6): 812-817.
[12] L. H. Sordia-Hernández, P. Ancer Rodríguez, D. Saldivar Rodriguez, S. Trejo Guzmán, E. S. Servín Zenteno, G. Guerrero González, R. Ibarra Patiño. Effect of a low glycemic diet in patients with polycystic ovary syndrome and anovulation - a randomized controlled trial[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(4): 555-559.
[13] W. Li, Y. Chen, L. Xu. Association of sympathetic nervous system activity with polycystic ovarian syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(5): 499-506.
[14] B.S. Unlu, H. Energin, Y. Yildiz, E. Unlu, E.G. Yapar Eyi. Maternal serum pregnancy-associated plasma protein-A levels in hyperemesis gravidarum: a prospective case control study[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(5): 534-536.
[15] L. Hu, H. Shen, Q.F. Wu, L. Tian, M.H. Hu. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(3): 288-292.
No Suggested Reading articles found!